{"id":"venetoclax-rituximab","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PANCYTOPENIA","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"P-gp inhibitors (e.g., cyclosporine, ketoconazole, itraconazole, erythromycin, clarithromycin, saquinavir, telithromycin, and voriconazole)","action":"Avoid","effect":"Increased venetoclax concentrations"},{"drug":"P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort)","action":"Avoid","effect":"Decreased venetoclax concentrations"},{"drug":"Strong CYP3A inhibitors (e.g., atazanavir, indinavir, nelfinavir, ritonavir, and saquinavir)","action":"Avoid","effect":"Increased venetoclax concentrations"},{"drug":"Strong CYP3A inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort)","action":"Avoid","effect":"Decreased venetoclax concentrations"},{"drug":"Live vaccines","action":"Avoid","effect":"Risk of infection"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Risk of infection"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of infusion reactions"},{"drug":"Immunosuppressants (e.g., azathioprine, cyclophosphamide, and methotrexate)","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Live attenuated influenza vaccine","action":"Avoid","effect":"Risk of infection"}],"commonSideEffects":[],"contraindications":["There is no information provided on contraindications for Venetoclax and Rituximab in the given text."],"specialPopulations":{"Pregnancy":"Rituximab use during pregnancy has raised concern for potential immune system effects in neonates. Clinicians should assess lymphocyte subset levels (T, B and NK cells) for newborns with rituximab exposure. No pattern of major structural anomalies or other adverse outcomes was reported in this case series.","Geriatric use":"text","Paediatric use":"Rituximab is used off label for JIA, multiple sclerosis and lupus. Three children aged 2 years before pregnancy, with the last infusion given no sooner than five half-lives before conception.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=venetoclax-rituximab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:34.690380+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:40.981011+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:34.717197+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=venetoclax-rituximab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:41.733523+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: B-lymphocyte antigen CD20 binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:42.353320+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201576/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:42.263047+00:00"}},"allNames":"venetoclax; rituximab","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Venetoclax and rituximab, when used in combination, represent a targeted therapy for certain hematologic malignancies. Venetoclax is a BCL-2 inhibitor that promotes apoptosis in cancer cells, while rituximab is a monoclonal antibody that targets CD20 on the surface of B-cells. The combination has shown efficacy in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Despite its therapeutic benefits, the regimen can cause significant side effects, including tumor lysis syndrome, neutropenia, and infections. The treatment is not approved by the FDA but is under investigation for various indications. Pfizer Inc. is developing this combination therapy to expand its oncology portfolio.","brandName":"Venetoclax; Rituximab","ecosystem":[],"isGeneric":true,"mechanism":{"target":"BCL-2 (venetoclax); CD20 (rituximab)","novelty":"The combination of venetoclax and rituximab represents a novel approach to treating hematologic malignancies by combining a targeted small molecule with an immunotherapy agent.","modality":"Small molecule (venetoclax); Biologic (rituximab)","drugClass":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","explanation":"","oneSentence":"","technicalDetail":"Venetoclax is a small molecule that selectively binds to the BCL-2 protein, disrupting its anti-apoptotic function. Rituximab is a chimeric monoclonal antibody that binds to the CD20 antigen on B-cells, leading to complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:51.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"N/A","revenueYear":2024,"annualCostUS":"","annualRevenue":2583,"genericStatus":"Biologic — patent protected","revenueSource":"SEC 8-K AbbVie (2025-01-31-AbbVie-Reports-Full-Year-and-Fourth-Qua)","currentRevenue":"","revenueCurrency":"USD","patientPopulation":"","peakSalesEstimate":"","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:48:24.972320","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=venetoclax-rituximab","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=venetoclax-rituximab","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:44.171628+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Venclexta (venetoclax)","company":"Venclexta","advantage":"BCL-2 inhibitor that may be used to treat chronic lymphocytic leukemia (CLL), small cell lymphoma (SCL)"},{"name":"Imbruvica","company":"Imbruvica","advantage":"Chronic Lymphocytic Leukemia"},{"name":"Ibrutinib","company":"Ibrutinib","advantage":"Chronic Lymphocytic Leukemia"},{"name":"Calquence","company":"Calquence","advantage":"Chronic Lymphocytic Leukemia"},{"name":"Acalabrutinib","company":"Acalabrutinib","advantage":"Chronic Lymphocytic Leukemia"},{"name":"Brukinsa","company":"Brukinsa","advantage":"Chronic Lymphocytic Leukemia"},{"name":"Jaypirca (pirtobrutinib)","company":"Jaypirca","advantage":"May also be used for purposes not listed in this medication guide"}],"genericName":"venetoclax-rituximab","indications":{"approved":[{"name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have received at least one prior therapy.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who are not eligible for or have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have received at least one prior therapy.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"},{"name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","regulator":"FDA"}],"offLabel":[],"pipeline":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT06943872","phase":"PHASE3","title":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-06-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":630},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT03523975","phase":"PHASE1, PHASE2","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-12-24","conditions":"Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT05947851","phase":"PHASE3","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma","enrollment":735},{"nctId":"NCT06510309","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2026-02-11","conditions":"Lymphoma, Marginal Zone Lymphoma, MZL","enrollment":33},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT06522386","phase":"PHASE2","title":"GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-30","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT03986034","phase":"PHASE2","title":"Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2019-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":75},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT06644183","phase":"PHASE1, PHASE2","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2025-03-19","conditions":"Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT04161248","phase":"EARLY_PHASE1","title":"Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-09-02","conditions":"Lymphoma, B-Cell","enrollment":18},{"nctId":"NCT04285268","phase":"PHASE2","title":"Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-05-06","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":0},{"nctId":"NCT04965493","phase":"PHASE3","title":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-20","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":600},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":72},{"nctId":"NCT03808610","phase":"PHASE1, PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT04843904","phase":"PHASE1","title":"Safe Accelerated Venetoclax Escalation in CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-14","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT03467867","phase":"PHASE2","title":"A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2018-04-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":"Lymphoma, Mantle-Cell","enrollment":141},{"nctId":"NCT03342144","phase":"","title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","status":"RECRUITING","sponsor":"AbbVie","startDate":"2017-12-04","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":500},{"nctId":"NCT05099471","phase":"PHASE2","title":"Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia","status":"RECRUITING","sponsor":"Christian Buske","startDate":"2025-03-21","conditions":"Waldenstrom Macroglobulinemia, Treatment Naive","enrollment":80},{"nctId":"NCT04010968","phase":"PHASE2","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2019-09-27","conditions":"Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy","enrollment":120},{"nctId":"NCT06362044","phase":"","title":"A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-06-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT07231952","phase":"PHASE2","title":"A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-11-11","conditions":"Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma","enrollment":40},{"nctId":"NCT05951959","phase":"PHASE2","title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":108},{"nctId":"NCT04981912","phase":"PHASE1","title":"Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-09-02","conditions":"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":0},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT04447716","phase":"PHASE1","title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-10-16","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma","enrollment":4},{"nctId":"NCT03834688","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2020-01-13","conditions":"Mantle Cell Lymphoma","enrollment":33},{"nctId":"NCT04416451","phase":"PHASE2","title":"A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-04","conditions":"Marginal Zone Lymphoma","enrollment":6},{"nctId":"NCT05555979","phase":"","title":"A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-12-14","conditions":"Chronic Lymphocytic Leukemia","enrollment":56},{"nctId":"NCT05025423","phase":"PHASE2","title":"Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-21","conditions":"Mantle Cell Lymphoma","enrollment":7},{"nctId":"NCT04752163","phase":"PHASE1, PHASE2","title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-25","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT03295240","phase":"EARLY_PHASE1","title":"The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-20","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":10},{"nctId":"NCT03576547","phase":"PHASE1, PHASE2","title":"Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-26","conditions":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia","enrollment":9},{"nctId":"NCT03492125","phase":"PHASE1, PHASE2","title":"A Study Of The Selective PKC-β Inhibitor MS- 553","status":"TERMINATED","sponsor":"MingSight Pharmaceuticals, Inc","startDate":"2018-05-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma","enrollment":60},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT02950051","phase":"PHASE3","title":"Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2016-12-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":926},{"nctId":"NCT03836261","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2019-02-25","conditions":"Chronic Lymphocytic Leukemia","enrollment":984},{"nctId":"NCT05069051","phase":"PHASE2","title":"Belimumab in Patients with Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2022-01-19","conditions":"Chronic Lymphoid Leukemia in Relapse","enrollment":120},{"nctId":"NCT03136497","phase":"PHASE1","title":"A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2017-09-05","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":10},{"nctId":"NCT04659044","phase":"PHASE2","title":"Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Academic and Community Cancer Research United","startDate":"2021-04-01","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma","enrollment":3},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT05864742","phase":"PHASE2","title":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-09-07","conditions":"Mantle Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":528},{"nctId":"NCT06471738","phase":"PHASE2","title":"Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-07-10","conditions":"Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":30},{"nctId":"NCT04790903","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-07-02","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":50},{"nctId":"NCT06496308","phase":"PHASE3","title":"Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-07-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":78},{"nctId":"NCT06247540","phase":"PHASE2","title":"Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2024-03-29","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":0},{"nctId":"NCT03455517","phase":"PHASE2","title":"Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2018-10-31","conditions":"Chronic Myeloid Leukemia","enrollment":77},{"nctId":"NCT02005471","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":389},{"nctId":"NCT02611323","phase":"PHASE1, PHASE2","title":"A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":133},{"nctId":"NCT04758975","phase":"PHASE2","title":"Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Paolo Ghia","startDate":"2022-09-19","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":55},{"nctId":"NCT01682616","phase":"PHASE1","title":"A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2012-07-25","conditions":"Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143},{"nctId":"NCT05209308","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL","status":"WITHDRAWN","sponsor":"MEI Pharma, Inc.","startDate":"2022-11-22","conditions":"CLL","enrollment":0},{"nctId":"NCT03064867","phase":"PHASE1, PHASE2","title":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Molly Gallogly","startDate":"2017-06-26","conditions":"Diffuse Large B-cell-lymphoma","enrollment":65},{"nctId":"NCT03036904","phase":"PHASE1","title":"Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-02-06","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma","enrollment":31},{"nctId":"NCT03255096","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-28","conditions":"Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma","enrollment":39},{"nctId":"NCT03135262","phase":"PHASE1, PHASE2","title":"A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-15","conditions":"Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":29},{"nctId":"NCT03639324","phase":"PHASE1","title":"Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2020-10-02","conditions":"Chronic Lymphocytic Leukemia, CLL, Relapsed CLL","enrollment":0},{"nctId":"NCT03505944","phase":"PHASE1, PHASE2","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Nordic Lymphoma Group","startDate":"2018-07-01","conditions":"Relapsed Non Hodgkin Lymphoma","enrollment":59},{"nctId":"NCT02265731","phase":"PHASE1, PHASE2","title":"Study Evaluating Venetoclax in Subjects With Hematological Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-22","conditions":"Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL)","enrollment":38},{"nctId":"NCT01594229","phase":"PHASE1","title":"A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2012-05-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":60},{"nctId":"NCT01742988","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma","status":"COMPLETED","sponsor":"Curis, Inc.","startDate":"2012-12","conditions":"Lymphoma, Relapsed Lymphoma, Refractory Lymphoma","enrollment":106},{"nctId":"NCT04000698","phase":"PHASE3","title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-10-15","conditions":"Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT01671904","phase":"PHASE1","title":"A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2014-01-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":84},{"nctId":"NCT02055820","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-17","conditions":"Lymphoma, Non-Hodgkin","enrollment":267},{"nctId":"NCT02187861","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-01","conditions":"Follicular Lymphoma","enrollment":163}],"_emaApprovals":[{"date":"","name":"Venetoclax; Rituximab","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":1,"reaction":"PANCYTOPENIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL1201576","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1201576"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":32,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:48:24.996519+00","biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar","pmid":"41722016","title":"Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil.","journal":"Oncology and therapy"},{"date":"2025 Sep 29","pmid":"41097687","title":"Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview.","journal":"Cancers"},{"date":"2025 Jun 30","pmid":"40722681","title":"Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications.","journal":"Biomedicines"},{"date":"2025 Jun 5","pmid":"40009494","title":"The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.","journal":"Blood"},{"date":"2024","pmid":"39391352","title":"Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis.","journal":"Therapeutic advances in medical oncology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:44.171628+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}